Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Entire DC Network
Effects Of Olanzapine And Betahistine Co-Treatment On Serotonin Transporter, 5-Ht2a And Dopamine D2 Receptor Binding Density, Jiamei Lian, Xu-Feng Huang, Nagesh Pai, Chao Deng
Effects Of Olanzapine And Betahistine Co-Treatment On Serotonin Transporter, 5-Ht2a And Dopamine D2 Receptor Binding Density, Jiamei Lian, Xu-Feng Huang, Nagesh Pai, Chao Deng
Xu-Feng Huang
Olanzapine is widely used in treating multiple domains of schizophrenia symptoms but induces serious metabolic side-effects. Recent evidence has showed that co-treatment of betahistine (a histaminergic H1 receptor agonist and H3 receptor antagonist) is effective for preventing olanzapine-induced weight gain/obesity, however it is not clear whether this co-treatment affects on the primary therapeutic receptor binding sites of olanzapine such as serotonergic 5-HT2A receptors (5-HT2AR) and dopaminergic D2 receptors (D2R). Therefore, this study investigated the effects of this co-treatment on 5-HT2AR, 5-HT transporter (5-HTT) and D2R bindings in various brain regions involved in antipsychotic efficacy. Female Sprague Dawley rats were administered …
Chronic Betahistine Co-Treatment Reverses Olanzapine's Effects On Dopamine D2 But Not 5-Ht2a/2c Bindings In Rat Brains, Jiamei Lian, Xu-Feng Huang, Nagesh B. Pai, Chao Deng
Chronic Betahistine Co-Treatment Reverses Olanzapine's Effects On Dopamine D2 But Not 5-Ht2a/2c Bindings In Rat Brains, Jiamei Lian, Xu-Feng Huang, Nagesh B. Pai, Chao Deng
Xu-Feng Huang
Olanzapine is widely prescribed for treating schizophrenia and other mental disorders, although it leads to severe body weight gain/obesity. Chronic co-treatment with betahistine has been found to significantly decrease olanzapine-induced weight gain; however, it is not clear whether this co-treatment affects the therapeutic effects of olanzapine. This study investigated the effects of chronic treatment of olanzapine and/or betahistine on the binding density of the serotonergic 5-HT2A (5-HT2AR) and 5-HT2C (5-HT2CR) receptors, 5-HT transporter (5-HTT), and dopaminergic D2 receptors (D2R) in the brain regions involved in antipsychotic efficacy, including the prefrontal cortex (PFC), cingulate cortex (Cg), nucleus accumbens (NAc), and caudate …